A Phase 2 interventional study of Guselkumab dose 1 and Guselkumab dose 2 in Hidradenitis Suppurativa, sponsored by Janssen Research & Development, LLC. Completed at 45 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 42nd largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2018, is one of 61 in phase 2, and was the 33rd registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 4 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
Drug: Guselkumab dose 1 · Drug: Guselkumab dose 2 · Drug: Placebo
Participants will receive guselkumab dose 2 subcutaneously.
Drug: Guselkumab dose 2 · Drug: Placebo
Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
Drug: Guselkumab dose 2 · Drug: Guselkumab dose 3 · Drug: Placebo
Participants will receive guselkumab dose 1 IV.
Also known as: CNTO 1959
Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
Also known as: CNTO 1959
Participants will receive guselkumab dose 3 SC in Group 3.
Also known as: CNTO 1959
Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
HiSCR is defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
Time frame: Week 16
Change From Baseline in Participant's Total Abscess and Inflammatory Nodule (AN) Count at Week 16
Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Baseline and Week 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
DLQI is a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (that is, negative change score) indicates improvement in the Quality of Life.
Time frame: Baseline and Week 16
Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Week 16
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours with a score range from 0 (no symptom experience) to 10 (worst possible symptom experience). A total symptom score also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period. Change from baseline in HS-related pain symptom score based on HSSD was reported.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved at Least 50 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16
Percentage of participants who achieved at least 50 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Week 16
Percentage of Participants Who Achieved at Least 75 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16
Percentage of participants who achieved at least 75 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Week 16
Percentage of Participants Who Achieved at Least 90 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16
Percentage of participants who achieved at least 90 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Week 16
Percentage of Participants Who Achieved 100 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16
Percentage of participants who achieved 100 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Week 16
Percentage of Participants Who Achieved an Abscess and Inflammatory Nodule Count of 0/1 and AN Count of 0/1/2 at Week 16
Percentage of participants who achieved an AN count of 0/1 and AN Count of 0/1/2 at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Week 16
Percentage of Participants Who Achieved Abscess Count of 0 at Week 16 For Participants With Baseline Abscess Count Greater Than 0
Percentage of participants who achieved abscess count of 0 at Week 16 for participants with baseline abscess count greater than (\>) 0 were reported.
Time frame: Week 16
Change From Baseline in the Number of Abscesses at Week 16
Change from baseline in number of abscesses at Week 16 was reported.
Time frame: Baseline and Week 16
Change From Baseline in HSSD Symptom Scale Total Score at Week 16
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. A total symptom score, also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period.
Time frame: Baseline and Week 16
Change From Baseline in HSSD Symptom Scale Score (Other Than Pain in the Past 24 Hours) at Week 16
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. Change from baseline in each individual HSSD component scale (other than pain in the past 24 hours) tenderness, hot skin feeling, odor and itchiness symptom, pain, and current pain score (rated on a scale of 0 \[no symptom experience\] to 10 \[worst possible symptom experience\]) were reported.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved Draining Fistula Count of 0 at Week 16 for Participants With Baseline Draining Fistula Count Greater Than 0
Percentage of participants who achieved draining fistulas count of 0 at Week 16 for participants with baseline draining fistula count \>0 were reported. Draining fistula were defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
Time frame: Week 16
Change From Baseline in Number of Draining Fistulas at Week 16
Change from baseline in number of draining fistulas at Week 16 was reported. Draining fistula are defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved Inflammatory Nodules Count of 0 at Week 16 for Participants With Baseline Inflammatory Nodule Count Greater Than 0
Percentage of participants who achieved inflammatory nodules count of 0 at Week 16 in participants with baseline inflammatory nodules count \>0 were reported.
Time frame: Week 16
Change From Baseline in Number of Inflammatory Nodules at Week 16
Change from baseline in number of inflammatory nodules at Week 16 was reported.
Time frame: Baseline and Week 16
Percentage of Participants With Hidradenitis Suppurativa-investigator's Global Assessment (HS-IGA) Score of Inactive (0), Almost Inactive (1), or Mild Activity (2) and With at Least 2-Grade Improvement Relative to Baseline at Week 16
The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline was evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1), or mild activity (2) and with at least 2-grade improvement relative to baseline at Week 16 were reported.
Time frame: Week 16
Percentage of Participants With HS-IGA Score of Inactive (0) or Almost Inactive (1) at Week 16 Among Participants With HS-IGA Score of Moderate Activity (3) or Severe Activity (4) at Baseline
The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline was evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. Among participants with score of moderate activity (3) or severe activity (4) at baseline, the same anatomic site selected for evaluation at the baseline were re-evaluated at Week 16. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1) at Week 16 among participants with HS-IGA score of moderate activity (3) or severe activity (4) at baseline were reported.
Time frame: Week 16
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 16
The HADS has been developed to identify symptoms of anxiety and depression in hospitalized participants and in outpatients. It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14. Each item receives a score from 0 to 3 on a Likert Scale. The total score for each HADS-A and HADS-D scale is obtained by adding the individual scores for each item, with the maximum score 21. The presence or absence of depression and anxiety was defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 equal to (=) no anxiety; greater than (\>) 9 = anxiety; HADS (depression): 0-8 = no depression; \>9 = depression.
Time frame: Baseline and Week 16
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP) at Week 16
Change from baseline in hs-CRP at Week 16 was reported. Serum samples were collected and analyzed for hsCRP. Change from Baseline was calculated as: (\[hs-CRP value at Week 16 minus Baseline value\] divided by \[Baseline value\]).
Time frame: Baseline and Week 16
Number of Participants With Patient Global Impression of Change (PGIC) of Hidradenitis Suppurativa Severity Scale Score at Week 16
The PGIC of HS Severity is a questionnaire that measures participants' perceived change (improvement or deterioration) in severity of their HS. Participants rated how his/her HS has changed since the beginning of the study using a 7-point scale ranging from 1 which indicates "a lot better now" to 7 which indicates "a lot worse now" with a neutral center point 4 which indicates ("neither better nor worse"). Participants' PGIC of HS Severity scale score at Week 16 were reported
Time frame: Week 16
| Milestone | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Placebo Crossover to Guselkumab 100 mg SC (Week 16 - 48) | Placebo Crossover to Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 1200 mg IV Crossover to Guselkumab 200 mg SC (Week 16 - 48) |
|---|---|---|---|---|---|---|---|
| Started | 62 | 59 | 60 | 0 | 0 | 0 | 0 |
| Completed | 56 | 56 | 57 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Placebo Crossover to Guselkumab 100 mg SC (Week 16 - 48) | Placebo Crossover to Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 1200 mg IV Crossover to Guselkumab 200 mg SC (Week 16 - 48) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 28 | 28 | 56 | 57 |
| Completed | 0 | 0 | 0 | 20 | 24 | 43 | 46 |
| Not completed | 0 | 0 | 0 | 8 | 4 | 13 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 2 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 5 | 1 | 4 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 5 | 3 |
HiSCR is defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 38.7 | 50.8 | 45.0 |
Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| count of abscess and inflammatory nodule | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in Participant's Total Abscess and Inflammatory Nodule (AN) Count at Week 16 | -3.2 ± 7.37 | -5.3 ± 9.29 | -5.3 ± 6.53 |
DLQI is a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (that is, negative change score) indicates improvement in the Quality of Life.
| units on a scale | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -0.7 ± 5.17 | -3.4 ± 6.81 | -2.5 ± 6.13 |
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours with a score range from 0 (no symptom experience) to 10 (worst possible symptom experience). A total symptom score also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period. Change from baseline in HS-related pain symptom score based on HSSD was reported.
| units on a scale | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) Questionnaire at Week 16 | -0.3 ± 3.17 | -1.6 ± 3.05 | -1.2 ± 2.93 |
Percentage of participants who achieved at least 50 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved at Least 50 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16 | 45.2 | 55.9 | 51.7 |
Percentage of participants who achieved at least 75 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved at Least 75 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16 | 30.6 | 40.7 | 26.7 |
Percentage of participants who achieved at least 90 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved at Least 90 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16 | 17.7 | 22.0 | 15.0 |
Percentage of participants who achieved 100 percent reduction in total AN count at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved 100 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16 | 14.5 | 15.3 | 15.0 |
Percentage of participants who achieved an AN count of 0/1 and AN Count of 0/1/2 at Week 16 were reported. Abscess and inflammatory nodule were counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| AN Count of 0/1 | 27.4 | 30.5 | 23.3 |
| AN Count of 0/1/2 | 33.9 | 39.0 | 31.7 |
Percentage of participants who achieved abscess count of 0 at Week 16 for participants with baseline abscess count greater than (\>) 0 were reported.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved Abscess Count of 0 at Week 16 For Participants With Baseline Abscess Count Greater Than 0 | 39.3 | 63.9 | 45.2 |
Change from baseline in number of abscesses at Week 16 was reported.
| abscess | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in the Number of Abscesses at Week 16 | -0.4 ± 2.72 | -2.1 ± 4.56 | -1.6 ± 3.90 |
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. A total symptom score, also ranged from 0 (no symptom) to 10 (worst possible symptom), was derived by averaging the 5 individual scale scores that utilize the past 7-day recall period.
| units on a scale | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in HSSD Symptom Scale Total Score at Week 16 | -0.19 ± 2.124 | -1.71 ± 2.325 | -0.82 ± 2.148 |
HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants were asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. Change from baseline in each individual HSSD component scale (other than pain in the past 24 hours) tenderness, hot skin feeling, odor and itchiness symptom, pain, and current pain score (rated on a scale of 0 \[no symptom experience\] to 10 \[worst possible symptom experience\]) were reported.
| units on a scale | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change in HSSD Tenderness Scale Score | -0.4 ± 2.78 | -2.1 ± 2.93 | -1.3 ± 2.56 |
| Change in HSSD Hot Skin Feeling Scale Score | 0.1 ± 2.85 | -1.6 ± 3.12 | -0.2 ± 3.16 |
| Change in HSSD Odor Scale Score | -0.4 ± 2.73 | -1.9 ± 2.58 | -1.2 ± 2.77 |
| Change in HSSD Itchiness Scale Score | 0.1 ± 2.82 | -1.1 ± 3.28 | -0.5 ± 2.85 |
| Change in HSSD Pain Scale Score | -0.3 ± 2.64 | -1.8 ± 2.86 | -0.9 ± 2.34 |
| Change in HSSD Current Pain Score | -0.4 ± 2.71 | -1.5 ± 2.94 | -1.2 ± 2.76 |
Percentage of participants who achieved draining fistulas count of 0 at Week 16 for participants with baseline draining fistula count \>0 were reported. Draining fistula were defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved Draining Fistula Count of 0 at Week 16 for Participants With Baseline Draining Fistula Count Greater Than 0 | 36.6 | 31.0 | 20.5 |
Change from baseline in number of draining fistulas at Week 16 was reported. Draining fistula are defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
| fistulas | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in Number of Draining Fistulas at Week 16 | -0.5 ± 2.87 | -1.7 ± 3.77 | -0.8 ± 2.08 |
Percentage of participants who achieved inflammatory nodules count of 0 at Week 16 in participants with baseline inflammatory nodules count \>0 were reported.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants Who Achieved Inflammatory Nodules Count of 0 at Week 16 for Participants With Baseline Inflammatory Nodule Count Greater Than 0 | 17.7 | 17.2 | 18.6 |
Change from baseline in number of inflammatory nodules at Week 16 was reported.
| inflammatory nodule | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in Number of Inflammatory Nodules at Week 16 | -2.8 ± 6.96 | -3.2 ± 7.84 | -3.7 ± 4.91 |
The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline was evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1), or mild activity (2) and with at least 2-grade improvement relative to baseline at Week 16 were reported.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| HS-IGA scores of inactive (0) | 16.1 | 13.6 | 13.3 |
| HS-IGA scores of inactive (0) or almost inactive (1) | 24.2 | 28.8 | 23.3 |
| HS-IGA scores of inactive (0), almost inactive (1), or mild activity (2) | 24.2 | 35.6 | 31.7 |
The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline was evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. Among participants with score of moderate activity (3) or severe activity (4) at baseline, the same anatomic site selected for evaluation at the baseline were re-evaluated at Week 16. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1) at Week 16 among participants with HS-IGA score of moderate activity (3) or severe activity (4) at baseline were reported.
| percentage of participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Percentage of Participants With HS-IGA Score of Inactive (0) or Almost Inactive (1) at Week 16 Among Participants With HS-IGA Score of Moderate Activity (3) or Severe Activity (4) at Baseline | 27.3 | 32.7 | 25.0 |
The HADS has been developed to identify symptoms of anxiety and depression in hospitalized participants and in outpatients. It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14. Each item receives a score from 0 to 3 on a Likert Scale. The total score for each HADS-A and HADS-D scale is obtained by adding the individual scores for each item, with the maximum score 21. The presence or absence of depression and anxiety was defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 equal to (=) no anxiety; greater than (\>) 9 = anxiety; HADS (depression): 0-8 = no depression; \>9 = depression.
| units on a scale | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| HADS-A | 0.0 ± 2.60 | 0.0 ± 2.82 | -0.3 ± 2.56 |
| HADS-D | 0.2 ± 2.48 | -0.6 ± 2.73 | -0.5 ± 2.69 |
Change from baseline in hs-CRP at Week 16 was reported. Serum samples were collected and analyzed for hsCRP. Change from Baseline was calculated as: (\[hs-CRP value at Week 16 minus Baseline value\] divided by \[Baseline value\]).
| milligrams per deciliter | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP) at Week 16 | -0.308 ± 8.0840 | 3.238 ± 19.0716 | -2.828 ± 11.1048 |
The PGIC of HS Severity is a questionnaire that measures participants' perceived change (improvement or deterioration) in severity of their HS. Participants rated how his/her HS has changed since the beginning of the study using a 7-point scale ranging from 1 which indicates "a lot better now" to 7 which indicates "a lot worse now" with a neutral center point 4 which indicates ("neither better nor worse"). Participants' PGIC of HS Severity scale score at Week 16 were reported
| Participants | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) |
|---|---|---|---|
| A lot better now | 4 | 13 | 10 |
| Moderately better now | 7 | 14 | 11 |
| A little better now | 16 | 10 | 12 |
| No change | 20 | 12 | 18 |
| A little worse now | 3 | 2 | 4 |
| Moderately worse now | 5 | 1 | 1 |
| A lot worse now | 1 | 4 | 0 |
Collected over Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Week 0 - 16) | 0/62 (0%) | 3/62 (4.8%) | 22/62 (35.5%) |
| Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | 0/59 (0%) | 1/59 (1.7%) | 28/59 (47.5%) |
| Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | 0/60 (0%) | 1/60 (1.7%) | 31/60 (51.7%) |
| Placebo Crossover to Guselkumab 100 mg SC (Week 16 - 48) | 0/28 (0%) | 3/28 (10.7%) | 12/28 (42.9%) |
| Placebo Crossover to Guselkumab 200 mg SC (Week 16 - 48) | 0/28 (0%) | 0/28 (0%) | 9/28 (32.1%) |
| Guselkumab 200 mg SC (Week 16 - 48) | 0/56 (0%) | 3/56 (5.4%) | 19/56 (33.9%) |
| Guselkumab 1200 mg IV Crossover to Guselkumab 200 mg SC (Week 16 - 48) | 0/57 (0%) | 2/57 (3.5%) | 28/57 (49.1%) |
| Event | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Placebo Crossover to Guselkumab 100 mg SC (Week 16 - 48) | Placebo Crossover to Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 1200 mg IV Crossover to Guselkumab 200 mg SC (Week 16 - 48) |
|---|---|---|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 0/62 | 0/59 | 0/60 | 2/28 | 0/28 | 0/56 | 0/57 |
| PneumoniaInfections and infestations | 0/62 | 0/59 | 0/60 | 1/28 | 0/28 | 0/56 | 0/57 |
| Depression SuicidalPsychiatric disorders | 0/62 | 0/59 | 0/60 | 1/28 | 0/28 | 0/56 | 0/57 |
| Diabetes MellitusMetabolism and nutrition disorders | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 1/56 | 0/57 |
| Acute Kidney InjuryRenal and urinary disorders | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 1/56 | 0/57 |
| Aortic AneurysmVascular disorders | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 1/56 | 0/57 |
| DysphagiaGastrointestinal disorders | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 0/56 | 1/57 |
| PancreatitisGastrointestinal disorders | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 0/56 | 1/57 |
| Septic ShockInfections and infestations | 0/62 | 0/59 | 0/60 | 0/28 | 0/28 | 0/56 | 1/57 |
| AnaemiaBlood and lymphatic system disorders | 0/62 | 1/59 | 0/60 | 0/28 | 0/28 | 0/56 | 0/57 |
| Event | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Placebo Crossover to Guselkumab 100 mg SC (Week 16 - 48) | Placebo Crossover to Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 200 mg SC (Week 16 - 48) | Guselkumab 1200 mg IV Crossover to Guselkumab 200 mg SC (Week 16 - 48) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/62 | 12/59 | 9/60 | 4/28 | 8/28 | 10/56 | 12/57 |
| HidradenitisSkin and subcutaneous tissue disorders | 1/62 | 3/59 | 7/60 | 2/28 | 4/28 | 6/56 | 4/57 |
| FatigueGeneral disorders | 2/62 | 2/59 | 7/60 | 0/28 | 1/28 | 1/56 | 2/57 |
| HeadacheNervous system disorders | 7/62 | 6/59 | 2/60 | 3/28 | 0/28 | 2/56 | 3/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/62 | 1/59 | 5/60 | 1/28 | 3/28 | 0/56 | 0/57 |
| DiarrhoeaGastrointestinal disorders | 6/62 | 2/59 | 6/60 | 0/28 | 0/28 | 4/56 | 1/57 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/62 | 3/59 | 5/60 | 1/28 | 0/28 | 1/56 | 3/57 |
| Oedema PeripheralGeneral disorders | 0/62 | 1/59 | 2/60 | 2/28 | 0/28 | 0/56 | 1/57 |
| Urinary Tract InfectionInfections and infestations | 1/62 | 0/59 | 0/60 | 2/28 | 0/28 | 0/56 | 2/57 |
| Skin PapillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/62 | 0/59 | 0/60 | 2/28 | 0/28 | 0/56 | 0/57 |
| Age, Categorical(Participants) | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 60 | 57 | 60 | 177 |
| >=65 years | 2 | 2 | 0 | 4 |
| Age, Continuous(years) | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Total |
|---|---|---|---|---|
| Mean | 38.2 ± 11.55 | 39 ± 12.37 | 37.2 ± 10.92 | 38.1 ± 11.58 |
| Sex: Female, Male(Participants) | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Total |
|---|---|---|---|---|
| Female | 38 | 32 | 45 | 115 |
| Male | 24 | 27 | 15 | 66 |
| Race (NIH/OMB)(Participants) | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 6 | 17 |
| White | 46 | 42 | 43 | 131 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 6 | 13 | 11 | 30 |
| Region of Enrollment(Participants) | Placebo (Week 0 - 16) | Guselkumab 200 Milligrams (mg) SC (Week 0 - 16) | Guselkumab 1200 mg IV to Gus 200 mg SC (Week 0 - 16) | Total |
|---|---|---|---|---|
| CANADA | 8 | 8 | 6 | 22 |
| DENMARK | 2 | 0 | 2 | 4 |
| FRANCE | 13 | 18 | 20 | 51 |
| GERMANY | 13 | 13 | 10 | 36 |
| NETHERLANDS | 3 | 1 | 3 | 7 |
| UNITED STATES | 23 | 19 | 19 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in May 2020, 20 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 20 months is above that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →